<p>Needham 分析师 Michael Matson 对 TFX 股票维持中性立场，于 12 月 7 日给予持有评级。</p>
<h3>TipRanks 网络星期一促销</h3>
<ul>
<li>申请 TipRanks Premium 享受 60% 的折扣，获取数据支持的洞察和研究工具，让您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据，现在也享受 60% 的折扣。</li>
</ul>
<p>Michael Matson 给予持有评级是由于 Teleflex 最近商业决策的多种因素。该公司宣布达成协议，出售其急救护理和介入泌尿科业务以及 OEM 业务，预计从这些交易中税后获得约 18 亿美元。这与之前估值的下限一致，表明谨慎的前景。</p>
<p>此外，Teleflex 计划将所得款项用于股票回购或偿还债务，这可能会稳定公司的财务状况，但可能不会显著提升增长前景。剩余公司的每股收益预测表明，市盈率暗示该股票目前的估值合理。这些因素共同构成了一个平衡的视角，证明持有评级是合理的，因为在当前条件下，该股票似乎既不被低估也不被高估。</p>
<p>在 12 月 7 日发布的另一份报告中，TR | OpenAI – 4o 也重申了对该股票的持有评级，目标价为 127.00 美元。</p>

泰利福

<p>Needham 分析师 Michael Matson 对 Teleflex (TFX) 股票维持持有评级，原因是战略性剥离和财务稳定化努力。Teleflex 计划出售其急救、介入泌尿学和 OEM 业务，预计税后收入为 18 亿美元。所得款项可能用于股票回购或偿还债务，虽然能稳定财务，但并未提升增长。该股票被认为是合理估值，因此维持持有评级。另一份报告也重申了持有评级，目标价为 127 美元</p>

<p>Needham analyst Michael Matson has maintained their neutral stance on TFX stock, giving a Hold rating on December 7.</p>
<div class="lb-trans"><p>Needham 分析师 Michael Matson 对 TFX 股票维持中性立场，于 12 月 7 日给予持有评级。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 网络星期一促销</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>申请 TipRanks Premium 享受 60% 的折扣，获取数据支持的洞察和研究工具，让您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据，现在也享受 60% 的折扣。</li>
</ul>
</div><p>Michael Matson has given his Hold rating due to a combination of factors surrounding Teleflex’s recent business decisions. The company announced agreements to sell its Acute Care and Interventional Urology business and its OEM business, expecting to receive approximately $1.8 billion after taxes from these transactions. This aligns with the lower end of previous valuation estimates, suggesting a cautious outlook.</p>
<div class="lb-trans"><p>Michael Matson 给予持有评级是由于 Teleflex 最近商业决策的多种因素。该公司宣布达成协议，出售其急救护理和介入泌尿科业务以及 OEM 业务，预计从这些交易中税后获得约 18 亿美元。这与之前估值的下限一致，表明谨慎的前景。</p>
</div><p>Furthermore, Teleflex plans to utilize the proceeds for share repurchases or debt repayment, which could stabilize the company’s financial position but may not significantly enhance growth prospects. The projected earnings per share for the remaining company, RemainCo, indicate a price-to-earnings ratio that suggests the stock is fairly valued at present. These elements collectively contribute to a balanced perspective, justifying the Hold rating as the stock appears neither undervalued nor overvalued given current conditions.</p>
<div class="lb-trans"><p>此外，Teleflex 计划将所得款项用于股票回购或偿还债务，这可能会稳定公司的财务状况，但可能不会显著提升增长前景。剩余公司的每股收益预测表明，市盈率暗示该股票目前的估值合理。这些因素共同构成了一个平衡的视角，证明持有评级是合理的，因为在当前条件下，该股票似乎既不被低估也不被高估。</p>
</div><p>In another report released on December 7, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $127.00 price target.</p>
<div class="lb-trans"><p>在 12 月 7 日发布的另一份报告中，TR | OpenAI – 4o 也重申了对该股票的持有评级，目标价为 127.00 美元。</p>
</div>

泰利福的战略性资产剥离和财务稳定性在合理估值的背景下，证明了持有评级的合理性